Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering

Reuters

2025/11/13

Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering

Xenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583593734"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583593734\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583593734?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583593734","market":"us","top_or_hot":-1,"title":"Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/XBIOW\">Xenetic Biosciences, Inc.</a> announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/XBIOW\">Xenetic Biosciences, Inc.</a> announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBIO","symbol_name":"Xenetic Biosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL8mrjgp:1","article_id":"2583593734","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583593734","pubTimestamp":1763041561,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XBIO":"Xenetic Biosciences Inc","BK4139":"生物科技"},"translate_title":"Xenetic Biosciences报告第三季度收入增加并完成390万美元的发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBIO":0.9},"content_text":"Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n    \n\nXenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}